Cargando…

Comparative effectiveness of natalizumab on cognition in multiple sclerosis: A cohort study

BACKGROUND: Cognitive impairment occurs in 40%–70% of persons with multiple sclerosis (MS). OBJECTIVE: To examine the effectiveness of natalizumab compared with other disease-modifying treatments (DMTs) on improving cognition as measured by the Symbol Digit Modalities Test (SDMT). METHODS: Data were...

Descripción completa

Detalles Bibliográficos
Autores principales:	Manouchehrinia, Ali, Larsson, Hanna, Karim, Mohammad Ehsanul, Lycke, Jan, Olsson, Tomas, Kockum, Ingrid
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2023
Materias:	Original Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10152556/ https://www.ncbi.nlm.nih.gov/pubmed/36789885 http://dx.doi.org/10.1177/13524585231153992

Ejemplares similares

Smoking Attributable Risk in Multiple Sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2022)

The familial risk and heritability of multiple sclerosis and its onset phenotypes: A case–control study
por: Boles, Graysen Steele, et al.
Publicado: (2023)

Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Serum IgG levels to Epstein-Barr and measles viruses in patients with multiple sclerosis during natalizumab and interferon beta treatment
por: Persson Berg, Linn, et al.
Publicado: (2022)

Blood neurofilament light levels segregate treatment effects in multiple sclerosis
por: Delcoigne, Bénédicte, et al.
Publicado: (2020)

The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
por: Sandgren, Sofia, et al.
Publicado: (2023)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse
por: McKay, Kyla A., et al.
Publicado: (2022)

Cognitive evolution in natalizumab-treated multiple sclerosis patients
por: Jacques, Francois H, et al.
Publicado: (2016)

Inflammation-related plasma and CSF biomarkers for multiple sclerosis
por: Huang, Jesse, et al.
Publicado: (2020)

Season of birth is associated with multiple sclerosis and disease severity
por: Stridh, P, et al.
Publicado: (2021)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis
por: Birkeldh, Ulrika, et al.
Publicado: (2017)

Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study
por: Song, Jie, et al.
Publicado: (2018)

Association between brain volume and disability over time in multiple sclerosis
por: Moridi, Thomas, et al.
Publicado: (2022)

Determinants of quality of life in pediatric- and adult-onset multiple sclerosis
por: McKay, Kyla A., et al.
Publicado: (2020)

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
por: Ganapathy Subramanian, Ranjani, et al.
Publicado: (2021)

Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study
por: Smith, Kelsi A, et al.
Publicado: (2023)

Low sun exposure increases multiple sclerosis risk both directly and indirectly
por: Hedström, Anna Karin, et al.
Publicado: (2019)

Confounding effect of blood volume and body mass index on blood neurofilament light chain levels
por: Manouchehrinia, Ali, et al.
Publicado: (2020)

Alcohol Consumption and Risk of Common Autoimmune Inflammatory Diseases—Evidence From a Large-Scale Genetic Analysis Totaling 1 Million Individuals
por: Jiang, Xia, et al.
Publicado: (2021)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in Sweden
por: Karampampa, Korinna, et al.
Publicado: (2022)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Association of Pre-Disease Body Mass Index With Multiple Sclerosis Prognosis
por: Manouchehrinia, Ali, et al.
Publicado: (2018)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
por: Hernández-Preciado, Martha Rocio, et al.
Publicado: (2022)

Disease-modifying therapies and cost-of-illness progression among people newly diagnosed with multiple sclerosis: a national register-based cohort study covering treatment initiation with interferons, glatiramer acetate or natalizumab
por: Karampampa, Korinna, et al.
Publicado: (2023)

Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort
por: Westerlind, Helga, et al.
Publicado: (2015)

Impact of Natalizumab Treatment on Fatigue, Mood, and Aspects of Cognition in Relapsing–Remitting Multiple Sclerosis
por: Kunkel, Annett, et al.
Publicado: (2015)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
por: Steinman, Lawrence
Publicado: (2012)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ret2b9gok4jss26qj4jfsglmfi